Iyiphi indima i-PARP inhibitors engayenza ekwelapheni umdlavuza webele? Izidakamizwa eziningana ezibizwa ngokuthi i-PARP inhibitors ziye zacwaningwa maduzane ekwelapheni umdlavuza webele. Ngabe lesi sigaba semithi siyini, futhi yini engaba khona ekugcineni kokuphathwa kwabantu abanomdlavuza webele?
Mayelana nokulungiswa kwe-PARP ne-DNA
I-PARP isichazamazwi se poly polysease (ADP-ribose) poly.
I-PARP iyi-protein enezindima ezimbalwa ezinkambisweni zamaselula, ikakhulukazi ekudaleni kwe-DNA nokufa kwe-cell (i-apoptosis). Amaseli aphilile angasebenzisa i-PARP ukuzilungisa wona futhi aphile umjikelezo wabo wokuphila ovamile. Kodwa amangqamuzana omdlavuza angasebenzisa i-PARP ukulungisa umonakalo we-DNA, ngaleyondlela ukwandisa ukukhula kwawo okungalawulwa. Amakhansela anjalo angakwazi ukumelana nemithi yokwelapha. Kukhona amaprotheni amaningi ehlukene wePARP, futhi ngamunye unendima yawo emisebenzini ngaphakathi kwamaseli.
I-PARP Inhibitors Nokwelashwa Kwebelevuza Sebele
I-PARP inhibitor ingumuthi ovimbela amaprotheni e-PARP ekwenzeni izindima zawo ekulungiseni amaseli omdlavuza abonakalisiwe. I-Chemotherapy nomsebenzi we- radiation ngokuphula i-DNA yamaseli ukuze bangabi nawo. Ezinye izinhlobo zamangqamuzana omdlavuza zisebenzisa ama-enzymes e-PARP ukulungisa umonakalo wazo we-DNA futhi alulame ekuhlaselweni kwemithi yomdlavuza. Kuhlolwa izinyathelo eziningana zokwelashwa ukuze ubone ukuthi i-PARP inhibitors, ehlangene neminye imithi yokwelashwa, ingavimbela amaprotheni e-PARP kusuka kumangqamuzana omdlavuza owonakele.
Imiphumela Emathanjeni Webele Kansa
Uma i-PARP inhibitor ingeziwe ekwelashweni kwe-chemotherapy yomdlavuza wesifuba, abacwaningi banethemba lokuthi amangqamuzana omdlavuza awenqabe izidakamizwa ze-antiticancer azobe esengozini yokulimala kweDNA. Kwezinye izimo, i-PARP inhibitor ingasetshenziswa yodwa , kunokuba ihlanganiswe ne-chemo nemisebe.
Ngisho nezindaba ezingcono kakhulu ukuthi i-PARP inhibitors ayibonakali ithinta amangqamuzana avamile, angenayo umdlavuza. Lokhu kusho imiphumela embalwa emibi yeziguli kanye nokuthola okusheshayo okuvela emithonjeni.
Ithemba leKhansela Yengculaza Yomzimba
I-PARP inhibitors ingase iwusize ikakhulukazi iziguli ezine-cancer yombelevuza webele. Abantu abane- BRCA1 ne- BRCA2 ukushintshashintsha kwezakhi zofuzo basengozini enkulu yokuthuthukisa umdlavuza webele. Izakhi zofuzo ze-BRCA ezempilo zikhiqiza amaprotheni angakwazi ukuvimbela ukubunjwa kwe-tumor ( abizwa ngokuthi i-tumor suppressor geni ), kodwa izakhi zofuzo ze-BRCA zashintsha amandla okwenza lezi proteins ezilwa namagciwane omdlavuza. I-PARP inhibitors ingase isebenzise ubuthakathaka obukhona emangqamuzaneni omdlavuza one-BRCA eguquliwe. Ukusetshenziswa okusemthethweni kwe-PARP inhibitors kungase kube ukuvimbela umdlavuza webele wefa . Mhlawumbe i-PARP inhibitors izoba ukwelashwa okuvimbela abesifazane abasengozini enkulu futhi ingenza izibalo ze-prophylactic zingasebenzi.
Ukugqugquzela Izindaba Zomdlavuza Wezinsongo Zezintathu Zesibili
Izivivinyo ezimbalwa zemitholampilo ye-PARP inhibitors ziye zathola inzuzo ethile yomtholampilo ngokungeza i-PARP inhibitor kwezinye izifo zokwelashwa komdlavuza wesifuba we-metastatic triple negative . Kulezi zifundo, ama-inhibitors e-PARP ayebekezelela kahle. Ngalesi sikhathi kuphela ukwelashwa okuhlosiwe okuhloswe ngomdlavuza wesifuba we-metastatic isvacizumab, kodwa le mithi ayinayo inzuzo eningi kubantu abanomdlavuza webele wesithathu.
Okunye ukusetshenziswa kwa-PARP Inhibitors
Izidakamizwa ezakhiwe nge-PARP inhibitors zivivinywa ngezinhlobo eziningana zomdlavuza: isifuba ne-ovarian, uterine, ubuchopho, ne-pancreatic. Ngo-2015, i-PARP inhibitor yamukelwa ukwelashwa kwamanye amagciwane e-ovarian.
Ukubaluleka Okubalulekile Kwe-PARP Inhibitors
Ukwengezwa kwe-PARP inhibitors esitokisini samanje sezikhali ezibhekene nomdlavuza wesifuba kubheka kakhulu. I-PARP inhibitors ikwandisa ukusebenza kahle kwe-chemotherapy ngokumelene namagciwane angamahlombe anezidakamizwa ezinesifo esibuhlungu kanye nesithathu, okungenzeka ngaphandle kokungeza imiphumela eminingi emibi kakhulu. Lezi zidakamizwa zibonakala zithuthukisa ikhwalithi yokuphila kanye nokwandisa ukusinda kweziguli.
Ukulwa nomdlavuza webele wezinga le-DNA yayo kubonakala sengathi ikusasa lekusasa.
> Imithombo:
> Boerner, J. et al. Amaphrotheni Ukuveza Amaprotheni Okulungisa Amademesheni E-DNA Aphendula Ukuphendula Kwama-Topoisomerase kanye ne-PARP Inhibitors E-Cancer Breast-negative Cancer. PLos One . 2015. 10 (3: e0119614.
> Woza, E., noMnu Robson. I-poly (ADP-ribose) i-Polymerase Inhibitors e-Triple-negative Breast Cancer. I-Cancer Journal . 2010. 16 (1): 48-52.
> Dizdar, O., Arslan, C., noK. Altundaq. Intuthuko e-PARP Inhibitors yokuPhathiswa kweCanscer Breast. I-Expert Opinion ku-Pharmacotherapy . 2015. 16 (18): 2751-8.
> Garber, J., noL. Livraghi. I-PARP Inhibitors ekuphathweni kwe-Cancer Breast: Idatha yamanje kanye namathemba esizayo. BMC Medicine . 2015. 13: 188.
> Hiller, D., no-Q. Chu. Isimo samanje sePoly (ADP-ribose) i-Polymerase Inhibitors njengezakhi zomshuwalense weNewvel for Cancer-Negative Breast Cancer. I-International Journal ye-Cancer Breast . 2012. 2012: 829315.
> Lee, J. et al. Isifundo se-Phase I / Ib se-Olaparib ne-Carboplatin ku-BRCA1 noma i-BRCA2 ehambisana ne-Breast or Ovarian Cancer With Biomarker Analyzes. Journal of the National Cancer Institute . 2014. 106 (6): dju089.
> O'Shaughnessy, J. et al. Iniparib Plus Chemotherapy ku-Metastatic Triple-negative Breast Cancer. I-New England Journal of Medicine . 2011. 364 (3): 205-14.
> O'Shaughnessy, J. et al. I-Journal ye-Clinical Oncology . 2014. 32 (34): 3840-7.
> O'Sullivan, C., Chen, A., no S. Kummar. Ukukhululwa esithembisweni: I-Poly ADP Ribose Polymerase Inhibition njengo-AnticancerT targeted Targeted. Umbono wamanje ku-Oncology . 2015. 27 (6): 475-81.
> Rios, J., noP. Puhalla. I-PARP Inhibitors e-Breast Cancer: i-BRCA ne-Beyond. I-Oncology (i-Williston park) . 2011. 25 (11): 1014-25.
> van der Noll, R. et al. Umsebenzi Wokuphepha Wesikhathi Eside Ne-Anti-Tumor Umsebenzi we-Olaparib Monotherapy Emva kokuhlanganiswa ne-Carboplatin ne-Paclitaxel kuziguli ezine-Advanced Breast, i-Ovarian noma i-Fallopian Tube umdlavuza. I-British Journal of Cancer . 2015. 113 (3): 396-402.